Related Experiment Video
Updated: Jul 20, 2026
08:42
Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)
Published on: June 27, 2025
Expression of cyclooxygenase-2 in Wilms tumor: immunohistochemical study using tissue microarray methodology
E Fridman1, J H Pinthus, J Kopolovic
1Department of Pathology, Chaim-Sheba Medical Center, Sackler School of Medicine, Tel-Aviv University, Ramat-Gan, 52621 Israel.
The Journal of Urology
|September 2, 2006
Summary
Cyclooxygenase-2 (COX-2) is highly expressed in most Wilms tumors, a common childhood kidney cancer. This finding suggests that COX-2 inhibitors may be a potential treatment for Wilms tumor.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Cyclooxygenase-2 (COX-2) is an enzyme crucial for prostaglandin synthesis, implicated in cell growth, inflammation, and apoptosis.
- COX-2 involvement in human neoplasms and the antitumor effects of its inhibitors are documented.
- COX-2 expression in Wilms tumor has not been previously investigated.
Purpose of the Study:
- To investigate the expression of cyclooxygenase-2 (COX-2) in Wilms tumor.
- To compare COX-2 expression in Wilms tumors with normal kidney tissues.
Main Methods:
- A tissue microarray was constructed using 14 Wilms tumor samples and xenografts.
- Normal human lung, liver, renal cortex, and medulla tissues served as controls.
- Immunohistochemistry with anti-COX-2 antibodies was performed and graded semiquantitatively.
Main Results:
- COX-2 was expressed in all non-anaplastic Wilms tumors and xenografts, across all cellular components except stroma.
- Expression was also noted in lung metastases and chemotherapy-resistant tumors.
- Normal kidney tissues showed less prominent COX-2 expression, localized to tubular epithelium.
Conclusions:
- COX-2 expression is a characteristic feature of non-anaplastic Wilms tumors.
- This expression pattern is similar to ErbB2 receptor pan-expression in these tumors.
- The therapeutic potential of COX-2 inhibitors warrants evaluation for Wilms tumor treatment.
